NCT05893693

Assess the Safety and Efficacy of CT0594CP Cells in Relapsed/Refractory Multiple Myeloma or Plasma Cell Leukemia

Open Label, Single Arm Clinical Trial to Evaluate the Safety and Efficacy of CT0594CP in Patients With Relapsed and/or Refractory Multiple Myeloma or Plasma Cell Leukemia

• Status: Unknown
• Phase: N/A
• Study type: Interventional
• Enrollment: 12 (estimated)
• Sponsor: Aibin Liang，MD，Ph.D. · Academic / Other
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

This is an open-label, single arm study to evaluate the safety and tolerability of treatment with CT0594CP CAR-T Cells in patients with relapsed and/or refractory multiple myeloma or Plasma Cell Leukemia

Detailed description

This is an open-label, single arm, dose-escalation clinical study, to evaluate the safety and tolerability of treatment with CT0594CP CAR-T Cells in patients with relapsed and/or refractory multiple myeloma or Plasma Cell Leukemia

Conditions

• Relapsed and/or Refractory Multiple Myeloma
• Plasma Cell Leukemia in Relapse

Interventions

Type	Name	Description
OTHER	Biological	CT0594CP

Timeline

• Start date: 2023-04-12
• Primary completion: 2026-01-01
• Completion: 2026-01-01
• First posted: 2023-06-08
• Last updated: 2023-06-08

Locations

1 site across 1 country: China